Safety

6
Pipeline Programs
6
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
Azilsartan medoxomil and chlorthalidonePhase 31 trial
Active Trials
NCT01309828Completed153Est. Oct 2012
FP
Fosun PharmaAustralia - Sydney
1 program
1
FCN-338 + AzacitidinePhase 21 trial
Active Trials
NCT06858618Active Not Recruiting47Est. Dec 2026
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD3043Phase 11 trial
Active Trials
NCT01086813Withdrawn0Est. Apr 2010
DS
Daiichi SankyoChina - Shanghai
1 program
1
DS-1971Phase 11 trial
Active Trials
NCT02107885Completed64Est. Jul 2014
Yirui Pharma
Yirui PharmaChina - Hangzhou
1 program
1
Kv1.3 potassium channel blockerPhase 11 trial
Active Trials
NCT07285967Not Yet RecruitingEst. Dec 2026
Cinclus Pharma
Cinclus PharmaSweden - Stockholm
1 program
1
Linaprazan gluratePhase 11 trial
Active Trials
NCT05627518Completed67Est. Jan 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaAzilsartan medoxomil and chlorthalidone
Fosun PharmaFCN-338 + Azacitidine
Yirui PharmaKv1.3 potassium channel blocker
Cinclus PharmaLinaprazan glurate
Daiichi SankyoDS-1971
AstraZenecaAZD3043

Clinical Trials (6)

Total enrollment: 331 patients across 6 trials

NCT01309828TakedaAzilsartan medoxomil and chlorthalidone

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Start: Mar 2011Est. completion: Oct 2012153 patients
Phase 3Completed
NCT06858618Fosun PharmaFCN-338 + Azacitidine

FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

Start: Aug 2023Est. completion: Dec 202647 patients
Phase 2Active Not Recruiting
NCT07285967Yirui PharmaKv1.3 potassium channel blocker

A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet

Start: Apr 2026Est. completion: Dec 2026
Phase 1Not Yet Recruiting
NCT05627518Cinclus PharmaLinaprazan glurate

Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation

Start: Nov 2022Est. completion: Jan 202367 patients
Phase 1Completed
NCT02107885Daiichi SankyoDS-1971

Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.

Start: Mar 2014Est. completion: Jul 201464 patients
Phase 1Completed
NCT01086813AstraZenecaAZD3043

Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043

Start: Mar 2010Est. completion: Apr 20100
Phase 1Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space